The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to ...
Lee — With a proposal by Vertex Towers LLC for a special permit to construct a 150-foot cell tower on Beaver Dam Road, the ...
In this webinar, sponsored by IPG Health, we will explore the role that cell and gene therapies can play in treating rare diseases, the unique challenges faced by pharmaceutical companies, healthcare ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.
Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...
The FDA has approved suzetrigine, a new, non-opioid medication for adults with moderate to severe acute pain.
While America retains a gold standard for airline safety, there are stresses on the US air travel system that have been apparent in a series of near tragedies ...
While it wasn’t found to be superior to that standard therapy for acute pain in both trials, Vertex’s drug offers the possibility to “fill the gap between medicines with good tolerability ...